Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

UCART123

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Cellectis, UT MD Anderson Cancer Center

Drug class:

CD123-targeted CAR-T immunotherapy

Related drugs:

‹

4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)

Autologous CAR-T cells (0)

CD123 CAR-T cell therapy (0)

CD123-CAR T cell therapy (0)

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (0)

anti-CD123 CAR-T (0)

4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)

Autologous CAR-T cells (0)

CD123 CAR-T cell therapy (0)

CD123-CAR T cell therapy (0)

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (0)

anti-CD123 CAR-T (0)

›

CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	UCART123 Sensitive: C2 – Inclusion Criteria UCART123 Sensitive : C2	UCART123 Sensitive: C2 – Inclusion Criteria UCART123 Sensitive : C2
CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	alemtuzumab + UCART123 Sensitive: C3 – Early Trials alemtuzumab + UCART123 Sensitive : C3	alemtuzumab + UCART123 Sensitive: C3 – Early Trials alemtuzumab + UCART123 Sensitive : C3